SMN2 and proximal spinal muscular atrophy: Health Canada approved Zolgensma for use in children 2 years or younger with infantile onset Spinal Muscular Atrophy (SMA) or those with 3 or fewer copies of SMN2. A subsequent review by CADTH recommended narrowing eligibility to patients under 6 months of age, citing a lack of efficacy data for patients older than 6 months.23 For patients and caregivers anxious for expeditious access whose children were older than 6 months, Zolgensma’s rapid path through clinical trials resulted in many unanswered questions.